BJP College Seminars Series
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KUPKA, R. W.
Right arrow Articles by POST, R. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by KUPKA, R. W.
Right arrow Articles by POST, R. M.
The British Journal of Psychiatry (2001) 178: s177-s183
© 2001 The Royal College of Psychiatrists

The Stanley Foundation Bipolar Network

2. Preliminary summary of demographics, course of illness and response to novel treatments{dagger}

RALPH W. KUPKA, MD1, WILLEM A. NOLEN, MD1, LORI L. ALTSHULER, MD2, KIRK D. DENICOFF, MD3, MARK A. FRYE, MD2, GABRIELE S. LEVERICH, MD3, PAUL E. KECK, Jr, MD4, SUSAN L. McELROY, MD4, A. JOHN RUSH, MD5, TRISHA SUPPES, MD5 and ROBERT M. POST, MD3

1 Altrecht Centre for Mental Health Care and University Medical Centre Utrecht, The Netherlands
2 University of California at Los Angeles and VA Medical Center, West Los Angeles, California, USA
3 Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland, USA
4 Biological Psychiatry Program, University of Cincinnati College of Medicine, Ohio, USA
5 University of Texas Southwestern Medical Center, Dallas, Texas, USA

Correspondence: Ralph Kupka, MD, Altrecht Centre for Mental Health Care, Vrouwjuttenhof 18, 3512 PZ Utrecht, The Netherlands. Tel: +31 30 230 8888; fax: +31 30 230 8885; e-mail: kupka{at}hcrg.nl

Declaration of interest Support received from the Theodore and Vada Stanley Foundation.

{dagger} See Paper 1, pp. s169–s176.

Background The Stanley Foundation Bipolar Network (SFBN) evaluates treatments, course and clinical and neurobiological markers of resonse in bipolar illness.

Aims To give a preliminary summary of emerging findings in these areas.

Method Studies with established and potentially antimanic, antidepressant and mood-stabilising agents range from open case series to double-blind randomised clinical trials, and use the same core assessment methodology, thereby optimising the comparability of the outcomes. The National Institute of Mental Health Life Chart Method is the core instrument for retrospective and prospective longitudinal illness description.

Results The first groups of patients enrolled show a considerable degree of past and present symptomatology, psychiatric comorbidity and functional impairment. There are associations of both genetic and early environmental factors with more severe courses of illness. Open case series with add-on olanzapine, lamotrigine, gabapentin or topiramate show a differential spectrum of effectiveness in refractory patients.

Conclusions The SFBN provides important new data for the understanding and treatment of bipolar disorder.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
R. M. POST, W. A. NOLEN, R. W. KUPKA, K. D. DENICOFF, G. S. LEVERICH, P. E. KECK Jr, S. L. McELROY, A. J. RUSH, T. SUPPES, L. L. ALTSHULER, et al.
The Stanley Foundation Bipolar Network: 1. Rationale and methods
The British Journal of Psychiatry, June 1, 2001; 178 (41): s169 - s176.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 2001 The Royal College of Psychiatrists.